LeadIQ logo
Learn more at LeadIQ.com

Insights

Uniquely Positioned in Biotechnology Humacyte's disruptive biotechnology platform focusing on bioengineered human tissues and organs puts them uniquely positioned in the market, presenting a significant sales opportunity for innovative medical solutions.

Strategic Funding and Development With recent financing of $30 million and strategic partnerships for developing advanced tissue constructs and organ systems, Humacyte showcases a strong financial position, potentially opening doors for sales collaborations and expansion.

Clinical Trial Success and Regulatory Recognition Humacyte's human acellular vessels (HAVs) in late-stage clinical trials have received expedited review and priority designation by the FDA and U.S. Secretary of Defense, indicating strong potential for successful product outcomes and sales in treating vascular applications.

Innovative Stem Cell Licensing Humacyte's recent licensing of stem cell lines from Pluristyx for diabetes treatment and BioVascular Pancreas using iPSCs showcases a commitment to innovation, creating sales opportunities for cutting-edge therapies in the biotechnology sector.

Market Resonance and Growth The consistent focus on developing a disruptive biotechnology platform to improve patient lives and transform medical practices has garnered attention and investments, reflecting market resonance and growth potential that can be leveraged for sales expansion.

Similar companies to Humacyte

Humacyte Tech Stack

Humacyte uses 8 technology products and services including jsDelivr, Microsoft Word, ADP Workforce Now, and more. Explore Humacyte's tech stack below.

  • jsDelivr
    Content Delivery Network
  • Microsoft Word
    Editors
  • ADP Workforce Now
    Human Capital Management
  • TweenMax
    Javascript Frameworks
  • jQuery UI
    Javascript Libraries
  • Buildout
    Real Estate Marketing
  • reCAPTCHA
    Security
  • Concur
    Travel And Expense Management

Media & News

Humacyte's Email Address Formats

Humacyte uses at least 1 format(s):
Humacyte Email FormatsExamplePercentage
FLast@humacyte.comJDoe@humacyte.com
53%
Last@humacyte.comDoe@humacyte.com
33%
First.Last@humacyte.comJohn.Doe@humacyte.com
12%
FirstLast@humacyte.comJohnDoe@humacyte.com
2%

Frequently Asked Questions

Where is Humacyte's headquarters located?

Minus sign iconPlus sign icon
Humacyte's main headquarters is located at 2525 E NC Highway 54 2525 E Hwy 54 Durham, NC 27713 US. The company has employees across 2 continents, including North AmericaEurope.

What is Humacyte's phone number?

Minus sign iconPlus sign icon
You can contact Humacyte's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Humacyte's stock symbol?

Minus sign iconPlus sign icon
Humacyte is a publicly traded company; the company's stock symbol is HUMA.

What is Humacyte's official website and social media links?

Minus sign iconPlus sign icon
Humacyte's official website is humacyte.com and has social profiles on LinkedIn.

How much revenue does Humacyte generate?

Minus sign iconPlus sign icon
As of October 2024, Humacyte's annual revenue reached $35M.

What is Humacyte's SIC code NAICS code?

Minus sign iconPlus sign icon
Humacyte's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Humacyte have currently?

Minus sign iconPlus sign icon
As of October 2024, Humacyte has approximately 218 employees across 2 continents, including North AmericaEurope. Key team members include Chief Regulatory Officer: B. T.Chief Financial Officer And Chief Corporate Development Officer: D. S.Chief Medical Officer: A. P.. Explore Humacyte's employee directory with LeadIQ.

What industry does Humacyte belong to?

Minus sign iconPlus sign icon
Humacyte operates in the Biotechnology Research industry.

What technology does Humacyte use?

Minus sign iconPlus sign icon
Humacyte's tech stack includes jsDelivrMicrosoft WordADP Workforce NowTweenMaxjQuery UIBuildoutreCAPTCHAConcur.

What is Humacyte's email format?

Minus sign iconPlus sign icon
Humacyte's email format typically follows the pattern of . Find more Humacyte email formats with LeadIQ.

How much funding has Humacyte raised to date?

Minus sign iconPlus sign icon
As of October 2024, Humacyte has raised $40M in funding. The last funding round occurred on Feb 29, 2024 for $40M.

When was Humacyte founded?

Minus sign iconPlus sign icon
Humacyte was founded in 2004.
Humacyte

Humacyte

Biotechnology ResearchNorth Carolina, United States201-500 Employees

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Section iconCompany Overview

Headquarters
2525 E NC Highway 54 2525 E Hwy 54 Durham, NC 27713 US
Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
HUMA
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2004
Employees
201-500

Section iconFunding & Financials

  • $40M

    Humacyte has raised a total of $40M of funding over 11 rounds. Their latest funding round was raised on Feb 29, 2024 in the amount of $40M.

  • $10M$50M

    Humacyte's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $40M

    Humacyte has raised a total of $40M of funding over 11 rounds. Their latest funding round was raised on Feb 29, 2024 in the amount of $40M.

  • $10M$50M

    Humacyte's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.